omegatherapeutics.com (OMGA): Enterprise Value to EBITDA Ratio
Omega Therapeutics (OMGA) focuses on developing epigenomic drugs, growing independently while relying on a strategic alliance with a global pharma leader to fund cardiovascular projects. The scaling of RNA therapy is driven by the implementation of bioreactors and robotics, which eliminates manual labor during screening. The price trend based on the EV/EBITDA metric is , while business success depends on scientific breakthroughs rather than economic cycles.
OMGA (omegatherapeutics.com): analytical breakdowns and indicator data
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Omega Therapeutics|OMGA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Omega Therapeutics, Inc.|OMGA - Aggregate Debt Obligations|Debts to Book Capitalization Omega Therapeutics Corp|OMGA - Company Long-Term Debts|Company Short-Term Debt Omega Therapeutics|Quick Ratio omegatherapeutics.com
- net income and valuation multiples indicators:
OMGA - Company Net Income|Future Profit Omega Therapeutics|OMGA - P/E Multiple|Projected Price to Earnings Omega Therapeutics|OMGA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Omega Therapeutics Corp|OMGA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Omega Therapeutics|OMGA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months omegatherapeutics.com|OMGA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Omega Therapeutics
Summary company analysis:Omega OMGA
This indicator assesses business value relative to its operating profit before depreciation, taxes, and interest, allowing for the determination of the investment attractiveness of capital-intensive assets. By analyzing the EV/EBITDA trajectory, an investor compares the total enterprise value with its ability to generate cash flow for debt servicing. For Omega Therapeutics (OMGA), this metric is critical while scaling the OMEGA platform and awaiting clinical results for the OTX-2002 drug.
Competitors of Omega Therapeutics
EV/EBITDA Multiple TEM (tempus.com)|EV/EBITDA Multiple Qiagen Corp QGEN|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRSP: Enterprise Value to Operating Income Before Depreciation Ratio|WGS (Sema4) - EV/EBITDA Multiple|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|SRPT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio WVE (wavelifesciences.com)|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to EBITDA Ratio PRME (Prime Medicine Corp)|EV/EBITDA Multiple Taysha Corp (TSHA)|uniQure N.V. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGTX (meiragtx.com)|REGENXBIO - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Solid Biosciences Inc SLDB|OCGN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PacBio Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma Inc.|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Pharmaceuticals, Inc. (RCKT)|FDMT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|KRRO - Enterprise Value to EBITDA Ratio|Editas Medicine, Inc. - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple silence-therapeutics.com (SLN)|PRQR: EV/EBITDA Multiple|Codexis (CDXS) - EV/EBITDA Multiple|SGMO (Sangamo) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation NAUT (Nautilus Biotechnology Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple GBIO (Generation Bio)|EV/EBITDA Multiple Boundless Bio Inc. BOLD|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Imunon, Inc.|phiopharma.com (PHIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Mustang Bio|RNAZ (TransCode Therapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Bionano BNGO|EV/EBITDA Multiple APDN|bluebird bio, Inc (BLUE) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple IPA (ImmunoPrecise Antibodies Ltd.)|EV/EBITDA Multiple singulargenomics.com OMIC|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals Inc.)|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TCON: Enterprise Value to Operating Income Before Depreciation Ratio|UBX (Unity Biotechnology) - EV/EBITDA Multiple
